Immufalk (Azathioprine)

Azathioprine is converted after ingestion to 6‑mercaptopurine, which interferes with purine synthesis. This blocks DNA replication in rapidly dividing cells, especially T and B lymphocytes, leading to reduced proliferation of these immune cells and consequently dampening the overall immune response.

The appropriate dose of Immufalk is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosage adjustments are made during treatment to balance efficacy with safety, and patients should follow the prescriber’s instructions precisely.

The safety of azathioprine during pregnancy or lactation is not definitively established and should be evaluated by the treating physician. In some cases, the benefits may outweigh potential risks, but a thorough risk‑benefit assessment and close monitoring are essential for pregnant or nursing patients.

To place an order, submit an enquiry on the Immufalk product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Azathioprine belongs to the antimetabolite class, differing from calcineurin inhibitors such as cyclosporine or tacrolimus. While all suppress immune activity, azathioprine primarily inhibits purine synthesis, offering a distinct side‑effect profile and dosing convenience (oral administration). Choice of agent depends on the clinical scenario, organ transplanted, and individual patient tolerance.

Immufalk should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Immufalk is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency are individualized, and patients should swallow the tablet whole with water, adhering to the dosing schedule provided by their healthcare professional.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, pancreatitis, opportunistic infections, and an increased long‑term risk of certain malignancies such as lymphoma. Patients should be monitored regularly for blood count and liver function abnormalities, and any concerning symptoms should be reported promptly.

Immufalk is contraindicated in individuals with known hypersensitivity to azathioprine or any of its components, and it should be avoided in patients with active severe infections. Caution is also advised for those with significant hepatic or renal impairment, and it is generally not recommended for pregnant or breastfeeding women without specialist guidance.